Cytoprotective Agents Used in the Treatment of Patients With Cancer

Seminars in Oncology Nursing

Volumn 23, Issue 3, 2007, Pages 213-224

  Hogle, William P ^a  

^a NONE

Author keywords

Cytoprotection; mucositis; xerostomia

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR; GLUTAMINE; MESNA; RAZOXANE;

ARTICLE; CELL PROTECTION; HUMAN; NEOPLASM; NURSING; PATHOLOGY;

AMIFOSTINE; ANTINEOPLASTIC AGENTS; CYTOPROTECTION; FIBROBLAST GROWTH FACTORS; GLUTAMINE; HUMANS; MESNA; NEOPLASMS; RAZOXANE;

EID: 34547657479     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2007.05.006     Document Type: Article

References (68)

1. Hensley M.L., Schuchter L.M., Lindley C., et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17 (1999) 3333-3335
2. Ethyol (amifostine) package insert (2005), MedImmune Oncology, Inc, Gaithersberg, MD September
3. Dorr R.T. Radioprotectants: pharmacology and clinical applications of amifostine. Semin Radiat Oncol 8 suppl 1 (1998) 10-13
4. Vincent M., Bramwell V., Moran L.A., et al. Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer. Curr Oncol 7 (2000) 149-161
5. Kintzel P.E. Anticancer drug-induced kidney disorders. Drug Saf 24 (2001) 19-38
6. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 (2000) 3339-3345
7. Wasserman T.H., Brizel D.M., Henke M., et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head and neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 63 (2005) 985-990
8. Koukourakis M.I., Kyrias G., Kakolyris S., et al. Subcutaneous administration of amifostine during fractionated radiotherapy: randomized phase II study. J Clin Oncol 18 (2000) 2226-2233
9. Anne P.R. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol 29 suppl 19 (2002) 80-83
10. Buntzel J., Kuttner K., Frohlich D., et al. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 9 (1998) 505-509
11. Antonadou D., Pepelassi M., Synodinou M., et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52 (2002) 739-747
12. Buntzel J., Micke O., Adamietz F.A., et al. Intravenous amifostine during chemoradiotherapy for head and neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 64 (2006) 684-691
13. Machtay M., Rosenthal D.I., Chalian A.A., et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 59 (2004) 72-77
14. Amrein P.C., Clark J.R., Supko J.G., et al. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer 104 (2005) 1418-1427
15. Saurel C. A phase I/II trial of induction chemotherapy followed by concomitant docetaxel with concomitant boost radiotherapy (CBR) and amifostine for advanced head and neck cancer. Proc Am Soc Clin Oncol (2006). http://www.asco.org [abstr 15525]. Available at www.asco.org.
16. Kemp G., Rose P., Lurain J., et al. Amifostine pretreatment for protection against cyclophosphamide and cisplatin-induced toxicities: results of a randomized controlled trial in patients with advanced ovarian cancer. J Clin Oncol 14 (1996) 2101-2112
17. DiPaola R., Rodriguez R., Goodin S., et al. Ethyol and dose intense paclitaxel in patients with advanced malignancies. Cancer Ther 1 (1998) 11-17
18. Akhtar S., Haider K., Bradshaw D., et al. Use of weekly one hour paclitaxel (P) infusion with dose escalation for recurrent or resistant cancers, using amifostine (AF) as a cytoprotector. Proc Am Soc Clin Oncol (2000). http://www.asco.org [abstr 838]. Available at www.asco.org.
19. Mitchell R.B. Amifostine to ameliorate the neurotoxicity of carboplatin/paclitaxel for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol (1998). http://www.asco.org [abstr 1906]. Available at www.asco.org.
20. Illiano A., Barletta E., Di Marino V., et al. Triplet chemotherapy combination with carboplatin (CBDCA), paclitaxel (TAX), and gemcitabine (GEM) plus amifostine (AMF) support in advanced NSCLC. Proc Am Soc Clin Oncol (2000). http://www.asco.org [abstr 2075]. Available at www.asco.org.
21. Hartmann J.T., Knop S., Fels L.M., et al. The use of reduced dose of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide based chemotherapy in patients with solid tumors. Anticancer Drugs 11 (2000) 1-6
22. Glover D., Grabelsky S., Fox K., et al. Clinical trials of WR-2721 and cisplatin. Int J Radiat Oncol Biol Phys 16 (1989) 1201-1204
23. Schiller J.H., Storer B., Berlin J., et al. Amifostine, cisplatin and vinblastine for metastatic non-small cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol (1996) 1913-1921
24. Bokemeyer C., Hartmann J.T., and Fels L. Amifostine protects against early cisplatin induced renal damage and enhances CD34+ cell numbers for PBSC collection. Proc Am Soc Clin Oncol (1997). http://www.asco.org [abstr 166]. Available at www.asco.org.
25. Breier S., Lebedinsky C., Pelayes L., et al. Amifostine, cisplatin and vinorelbine in non-small cell lung cancer. Proc Am Soc Clin Oncol (1997). http://www.asco.org [abstr 1664]. Available at www.asco.org.
26. Mollman J.E., Glover D.J., Hogan W.M., et al. Cisplatin neuropathy: risk factors, prognosis and protection by WR-2721. Cancer 61 (1988) 2192-2195
27. Moore D.H. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel- induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 21 (2003) 4207-4213
28. Hilpert F., Stahle A., Tome O., et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy-a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Cancer Care 13 (2005) 797-805
29. Albers J., Chaudhry V., Cavaletti G., et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 24 (2007) [abstr]
30. National Cancer Institute. Gynecologic Cancer Intergroup (GCIG) Clinical Trials. Available at. http://ctep.cancer.gov/resources/gcig/activetrials.html. (accessed November 22, 2006).
31. Gelmon K., Eisenhower E., Bryce C., et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 10 (1999) 3038-3047
32. Kanat O., Evrensel T., Baran I., et al. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. Med Oncol 20 (2003) 237-245
33. Lorusso D., Ferrandina G., Greggs S., et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 14 (2003) 1086-1093
34. Openshaw H. Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 10 (2004) 461-467
35. Ndubisi B.U., Guthrie T., Benrubi G., et al. A phase II open-label study to evaluate the use of amifostine (Ethyol) in reversing chemotherapy-induced peripheral neuropathy (PN) in cancer patients-preliminary findings. Proc Am Soc Clin Oncol (1999). http://www.asco.org [abstr 2326]. Available at www.asco.org
36. Zinecard (dexrazoxane) package insert (2005), Pfizer Inc, New York, NY December
37. Loerzel V.W., and Dow K.H. Cardiac toxicity related to cancer treatment. Clin J Oncol Nurs 7 (2003) 557-562
38. Speyer J.L., Green M.D., Kramer E., et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319 (1988) 745-752
39. Speyer J.L., Green M.D., Zeleniuch-Jacquotte A., et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10 (1992) 117-127
40. Swain S.M., Whaley F.S., Gerber M.C., et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15 (1997) 1318-1332
41. Swain S.M., Whaley F.S., Gerber M.C., et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15 (1997) 1333-1340
42. Marty M., Espie M., Llombart A., et al. A phase III study to investigate the cardioprotective potential of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients undergoing anthracycline-based chemotherapy. 27th Breast Cancer Symposium (2004) [abstr/poster 5052]. December 8-11, San Antonio, TX
43. Lima M.V., Ferreira F.V., Macedo F.Y., et al. Histologic changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis. Cancer Chemother Pharmacol 59 (2007) 643-650
44. Burkert H. Clinical overview of mesna. Cancer Treat Rev 10 suppl A (1983) 175-181
45. Brock N., and Pohl J. The development of mesna for regional detoxification. Cancer Treat Rev 10 supp A (1983) 33-43
46. Cox P.J., and Abel G. Cyclophosphamide cystitis. Studies aimed at its minimization. Biochem Pharmacol 28 (1979) 3499-3502
47. Scheef W., Klein H.O., Brock N., et al. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat Rep 63 (1979) 501-505
48. Bryant B.M., Jarman M., Ford H.T., et al. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 2 (1980) 657-559
49. Andriole G.L., Sandlund J.T., Miser J.S., et al. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. J Clin Oncol 5 (1987) 799-803
50. Danilenko D.M. Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol 27 (1999) 64-71
51. Steiling H., and Werner S. Fibroblast growth factors: key players in epithelial morphogenesis, repair, and cytoprotection. Curr Opin Biotech 14 (2003) 533-537
52. Spielberger R., Stiff P., Bensinger W., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351 (2004) 2590-2598
53. Brizel D., Le Q., Rosenthal D., et al. Phase 2 study of recombinant human keratinocyte growth factor (RHuKGF) in head and neck cancer treated with standard (SRT) or hyperfractionated irradiation (HRT) and concurrent chemotherapy (CT). Proc Am Soc Radiol Oncol (2002). http://www.astro.org [abstr 2128]. Available at www.astro.org
54. Rosen L.S., Abdi E., Davis I.D., et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 24 (2006) 5194-5200
55. Miller A.L. Therapeutic considerations of L-glutamine: a review of the literature. Alt Med Rev 4 (1999) 239-248
56. Smith R.J. Glutamine metabolism and its physiological importance. J Parent Enter Nutr 14 suppl 4 (1999) 94S-99S
57. Lebow B.I., and Souba W.W. Glutamine. World J Surg 24 (2000) 1503-1513
58. Medina M.A. Glutamine and cancer. J Nutr 131 suppl 9 (2001) 2539S-2542S
59. Jebb S.A., Osborne R.J., Maughan T.S., et al. 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine. Br J Cancer 70 (1994) 732-735
60. Okuno S.H., Woodhouse C.O., Loprinzi C.L., et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving 5-flourouracil (5-FU)-based chemotherapy. Am J Clin Oncol 22 (1999) 258-261
61. Anderson P.M., Schroeder G., Skubitz K.M., et al. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 83 (1998) 1433-1439
62. Decker-Baumann C., Buhl K., Frohmuller S., et al. Reduction of chemotherapy-induced side effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. Eur J Cancer 35 (1999) 202-207
63. Peterson DE, Petit RG. Oral mucositis incidence and severity reduced with AES-14. results of a phase III pivotal trial in patients with breast cancer [poster]. Presented at 1st Annual Chicago Supportive Oncology Conference (CSOC); October 6-8, 2005: Chicago, IL.
64. Huang E.Y., Leung S.W., Wang C.J., et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys 46 (2000) 535-539
65. Klimberg V.S., Rubio I., Kaufmann Y., et al. Effect of glutamine on radiation morbidity in breast conservation therapy is associated with a novel protein marker. 27th Breast Cancer Symposium (2004) [abstr 4037]. December 8-11, San Antonio, TX
66. Schuchter L.M., Hensley M.L., Meropol N.J., et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20 (2002) 2895-2903
67. Cancer Care Ontario Guidelines. The role of amifostine as a radioprotectant in the management of patients with squamous cell head and neck cancer. Available at. http://www.cancercare.on.ca/pdf/pebc5-8s.pdf (accessed November 22, 2006).
68. Rubenstein E.B., Peterson D.E., Schubert M., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100 suppl (2004) 2026-2046